Research and Markets: The Patent Cliff: How Pfizer has responded to the loss of its best-selling drug

<0> Research and Markets: The Patent Cliff: How Pfizer has responded to the loss of its best-selling drug </0>

<0> Research and MarketsLaura Wood, Senior ManagerU.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the company profile to their offering.

The pharmaceuticals market was worth $733bn in 2010. The top four market players (Pfizer Limited, Merck & Co., AstraZeneca, and GlaxoSmithKline) had a market share of 22.3%. Pfizer has been involved in many mergers and acquisitions. With some of these acquisitions came the rights to blockbuster drugs such as Lipitor (produced by Warner-Lambert) and Prevnar (produced by Wyeth).

MarketLine Case Studies describe topics such as innovative products, business models, and significant company acquisitions.

Fact-based and presented in an accessible style, they explain the rationale of commercial decisions and illustrate wider market and economic trends. Research and analysis highlights

The largest generics market in Asia is China, where generics grew to account for 62% of the total domestic pharmaceuticals market in 2008, from 54% in 1999. By 2015, China is predicted to become the world's second largest pharmaceutical market .

In 2011, Lipitor, Zyprexa, Levaquin, Concerta, and Protonix lost their patents. In 2012, Plavix, Seroquel, Singulair, Actos, and Enbrel will lose theirs. These 10 drugs alone had US sales of $30.5bn in 2010.

Overview 2

Analysis 5

Pharmaceutical market overview 5

The pharmaceuticals market has experienced strong, steady growth 6

Generics are becoming increasingly popular, particularly in "pharmerging" countries 7

Many of the world's best-selling drugs are losing their patents 8

Johnson & Johnson is diversifying its operations 9

Research and development productivity is in decline 9

Many companies are engaging in M&A activity 11

Pfizer has acquired companies that have existing products 12

In 2000, Pfizer acquired Warner-Lambert and its best-selling drug Lipitor 13

Pfizer's acquisition of Wyeth allowed it to diversify its product portfolio 13

Pfizer acquired King Pharmaceuticals, a company with a painkillers focus 14

Pfizer is responding to the increasing value of pharmerging markets 14

Conclusions 15

Generics and pharmerging markets may change the face of the pharmaceuticals market 15

Appendix 16

For more information visit

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.